Rosiglitazone reduces plasma insulin & its precursors while decreasing glycaemia in type 2 diabetics.

被引：0
|
作者：
Jones, NP
Charbonnel, B
Lönnqvist, F
Owen, S
Patwardhan, R
机构：
来源：
DIABETOLOGIA | 1999年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
859
引用
下载
收藏
页码：A229 / A229
页数：1
相关论文
共 50 条
  • [41] Rosiglitazone improves insulin sensitivity associated with body fat redistribution, a decreased plasma free fatty acid and increased adiponectin level in Asians with type 2 diabetes
    Deng, H
    Deng, H
    DIABETES, 2005, 54 : A527 - A527
  • [42] EFFECT OF DIETARY FIBER ON BLOOD-GLUCOSE, PLASMA-IMMUNOREACTIVE INSULIN, C-PEPTIDE AND GIP RESPONSES IN NON INSULIN DEPENDENT (TYPE-2) DIABETICS AND CONTROLS
    HAGANDER, B
    SCHERSTEN, B
    ASP, NG
    SARTOR, G
    AGARDH, CD
    SCHREZENMEIR, J
    KASPER, H
    AHREN, B
    LUNDQUIST, I
    ACTA MEDICA SCANDINAVICA, 1984, 215 (03): : 205 - 213
  • [43] PLASMA-GLUCOSE, INSULIN, C-PEPTIDE AND GLUCAGON-LEVELS AFTER A PROTEIN MEAL COMBINED WITH CORTISOL INFUSION IN TYPE-2 DIABETICS
    FERLITO, S
    DIVINCENZO, S
    INDELICATO, G
    DELCAMPO, F
    FICHERA, C
    PALERMO, F
    IRCS MEDICAL SCIENCE-BIOCHEMISTRY, 1984, 12 (01): : 73 - 74
  • [44] An acute bout of whole body passive hyperthermia increases plasma leptin, but does not alter glucose or insulin responses in obese type 2 diabetics and healthy adults
    Rivas, Eric
    Newmire, Dan E.
    Crandall, Craig G.
    Hooper, Philip L.
    Ben-Ezra, Vic
    JOURNAL OF THERMAL BIOLOGY, 2016, 59 : 26 - 33
  • [45] Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose
    Clemmons, DR
    Moses, AC
    Sommer, A
    Jacobson, W
    Rogol, AD
    Sleevi, MR
    Allan, G
    GROWTH HORMONE & IGF RESEARCH, 2005, 15 (04) : 265 - 274
  • [46] Insulin detemir maintains body weight and reduces hypoglycemia while improving glycemic control in type 1 and 2 patients:: 6-month results from Predictive™
    Lueddeke, Mans-Joachim
    Honka, Marek
    Hansen, Jes B.
    King, Allen
    DIABETES, 2007, 56 : A575 - A575
  • [47] Initial treatment with rosiglitazone (RSG) and glimepiride (GLIM) fixed-dose combination (FDC) reduces cardiovascular risk markers and improves insulin sensitivity in patients with type 2 diabetes (T2DM)
    Goldstein, Barry J.
    Segiet, Thomas S. E.
    Ferreira-Cornwell, Celeste
    Krebs, Jacqueline B.
    Chou, Hubert S.
    DIABETES, 2006, 55 : A113 - A113
  • [48] Plasma Fractalkine is Associated With Adipose Tissue Insulin Resistance and Low-Dose Pioglitazone Reduces Fractalkine Parallel With Reduced Adipose Tissue Insulin Resistance in Type 2 Diabetes
    Daniele, Giuseppe
    Perez-Cadena, Zandra
    Chavez-Velazquez, Alberto
    Kamath, Subhash
    Zuo, Penguo
    Chang, Zhi
    Andreozzi, Francesco
    Paez, Ana M.
    Fanti, Paolo
    Gastaldelli, Amalia
    Defronzo, Ralph
    Tripathy, Devjit
    Folli, Franco
    DIABETES, 2012, 61 : A264 - A264
  • [49] Study on glycaemic control by canagliflozin and its effect on insulin resistance and plasma ketone in type 2 diabetes mellitus patients
    Kumar, J. S.
    Karthickeyan, K.
    Patel, Bansi R.
    Meeran, K. I. Haroon
    Karishma, G.
    Raveendran, Vishnu T.
    JOURNAL OF DIABETOLOGY, 2019, 10 (02) : 83 - 86
  • [50] Pioglitazone treatment reduces hepatic fat content, enhances hepatic insulin sensitivity, and increases plasma adiponectin concentration in patients with Type 2 diabetes.
    Bajaj, M
    Suraamornkul, S
    Glass, L
    Cersosimo, E
    DeFronzo, R
    DIABETOLOGIA, 2003, 46 : A61 - A62
12345